Opioid antagonists: all 625 studies that test it

Page 2 of 7. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.

• The Use of Oral Naloxone to Prevent Post Spinal Fusion IleusTerminatedNCT03176316Phase 4Results posted
• Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in SchizophreniaTerminatedNCT03132571Phase 2Results posted
• Buprenorphine as Adjunct to Outpatient Induction Onto VivitrolTerminatedNCT03113409Phase 2/3Results posted
• Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative HyperalgesiaCompletedNCT03096730Not applicableResults posted
• Sensory and Opioid Mechanisms of Affective TouchCompletedNCT03096353Early Phase 1Results posted
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerTerminatedNCT03087708Phase 2Results posted
• Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use DisorderCompletedNCT03078075Phase 3Results posted
• To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced ConstipationCompletedNCT03060512Phase 4Results posted
• Low Dose Naltrexone for Chronic Pain From ArthritisCompletedNCT03008590Phase 2Results posted
• Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court SettingsCompletedNCT02978417Phase 4Results posted
• Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered OpioidsTerminatedNCT02977286Phase 4Results posted
• Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery PatientsTerminatedNCT02946580Phase 4Results posted
• Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical HomeCompletedNCT02885311Phase 1/2Results posted
• A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT02873208Phase 3Results posted
• An Open Label Trial of Bupropion and Naltrexone for Binge DrinkingCompletedNCT02842073Phase 2Results posted
• Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)TerminatedNCT02839889Phase 4Results posted
• An fMRI Study of Opioid-related Changes in Neural ActivityCompletedNCT02818036Not applicableResults posted
• Biology and Experience of Eating in Women With ObesityCompletedNCT02805972Phase 2Results posted
• Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?CompletedNCT02800928Phase 2Results posted
• Naloxegol in Cancer Opioid-Induced ConstipationTerminatedNCT02745353Phase 2Results posted
• Naltrexone and Bupropion Combination on Obese,Smoking Patients With SchizophreniaCompletedNCT02736474Phase 4Results posted
• Intra-nasal Naloxone for Treatment of Impaired Awareness of HypoglycemiaTerminatedNCT02700048Phase 1/2Results posted
• Combining Varenicline and Naltrexone for Smoking CessationCompletedNCT02698215Phase 2Results posted
• Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROLCompletedNCT02696434Phase 3Results posted
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)CompletedNCT02694328Phase 3Results posted
• A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male SubjectsCompletedNCT02679469Phase 1Results posted
• A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT02669758Phase 3Results posted
• Naltrexone/Bupropion Cardiovascular Outcomes StudyTerminatedNCT02638129Phase 4Results posted
• Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable NaltrexoneCompletedNCT02617628Phase 2/3Results posted
• Naloxone for Optimizing Hypoxemia Of Lung DonorsCompletedNCT02581111Phase 2/3Results posted
• Alcohol Disorder hOsPital Treatment TrialCompletedNCT02478489Phase 4Results posted
• Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use DisorderCompletedNCT02461927Phase 1/2Results posted
• A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and SolutionCompletedNCT02446171Phase 1Results posted
• Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department UsersCompletedNCT02445339Phase 4Results posted
• JKB-121 for the Treatment of Nonalcoholic SteatohepatitisCompletedNCT02442687Phase 2Results posted
• Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With MorphineCompletedNCT02403830Phase 4Results posted
• A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol DependenceCompletedNCT02382276Phase 3Results posted
• A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)CompletedNCT02364947Phase 3Results posted
• Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)CompletedNCT02330419Phase 2Results posted
• Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use DisordersCompletedNCT02322047Phase 2Results posted
• Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus PlaceboCompletedNCT02317744Not applicableResults posted
• Buprenorphine/Naloxone Stabilization and Induction Onto Injection NaltrexoneCompletedNCT02294253Phase 2/3Results posted
• Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2aCompletedNCT02218736Phase 2Results posted
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderCompletedNCT02161718Phase 2Results posted
• Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast CancerTerminatedNCT02137252Phase 2Results posted
• Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)CompletedNCT02110264Phase 3Results posted
• Low Dose Naltrexone (LDN) Immune MonitoringCompletedNCT02107014Not applicableResults posted
• Study of Long-Acting Injectable Naltrexone to Treat Cannabis DependenceCompletedNCT02088177Phase 1/2Results posted
• Extended-Release Naltrexone vs. Buprenorphine for Opioid TreatmentCompletedNCT02032433Phase 4Results posted
• Naltrexone for Individuals of East Asian DescentCompletedNCT02026011Phase 2Results posted
• Extended-Release Naltrexone Opioid Treatment at Jail Re-EntryCompletedNCT01999946Phase 4Results posted
• The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy VolunteersCompletedNCT01999114Phase 1Results posted
• Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))CompletedNCT01993108Phase 4Results posted
• Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use DisorderCompletedNCT01982643Phase 1/2Results posted
• Prescription Opioid Abuse Among Pain Patients: Predictors of RelapseCompletedNCT01967641Phase 2Results posted
• Study of Human Non-Shivering Thermogenesis and Basal Metabolic RateCompletedNCT01950520Phase 2Results posted
• Buprenorphine to Improve HIV Care Engagement and OutcomesCompletedNCT01936857Phase 4Results posted
• Harm Reduction With Pharmacotherapy (HaRP)CompletedNCT01932801Phase 2Results posted
• Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant DepressionTerminatedNCT01913535Phase 2Results posted
• Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness StudyCompletedNCT01908062Phase 3Results posted
• A Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT01903837Phase 2Results posted
• Nalrexone Facilitated Discontinuation of BuprenorphineCompletedNCT01895036Phase 1/2Results posted
• Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary CareCompletedNCT01893827Phase 4Results posted
• Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer PainCompletedNCT01885182Phase 3Results posted
• Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic PainTerminatedNCT01875848Phase 4Results posted
• Low-Dose Naltrexone (LDN) for Depression Relapse and RecurrenceCompletedNCT01874951Phase 2Results posted
• An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.CompletedNCT01873729Phase 4Results posted
• Naltrexone for Antipsychotic-Induced Weight GainCompletedNCT01866098Not applicableResults posted
• Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol DependenceCompletedNCT01856712Phase 3Results posted
• Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired SubjectsCompletedNCT01846455Phase 4Results posted
• Dane County Drug Court Study for Addicted OffendersCompletedNCT01843751Phase 3Results posted
• Extended Release Naltrexone for Opioid-Dependent YouthCompletedNCT01843023Phase 4Results posted
• Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain PatientsTerminatedNCT01841931Phase 4Results posted
• Risky Decision Making in Methamphetamine Users: The Role of Opioid BlockadeCompletedNCT01822132Not applicableResults posted
• An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal DisordersCompletedNCT01811238Phase 4Results posted
• An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)CompletedNCT01811186Phase 4Results posted
• A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity DisorderTerminatedNCT01721330Phase 4Results posted
• PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer PainCompletedNCT01719757Phase 4Results posted
• Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid DependenceCompletedNCT01690546Phase 2Results posted
• Prevention of Stimulant-Induced Euphoria With an Opioid Receptor AntagonistCompletedNCT01673594Phase 4Results posted
• Neuropharmacological Basis of Social Connection: The Role of OpioidsCompletedNCT01672723Not applicableResults posted
• Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal CancerTerminatedNCT01650350Phase 2Results posted
• Kappa-PET Imaging and Naltrexone in Alcohol Drinking BehaviorsCompletedNCT01625611Phase 1Results posted
• Clinical Trial to Reduce Drinking in Women With HIVCompletedNCT01625091Phase 3Results posted
• Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)TerminatedNCT01601704Phase 3Results posted
• CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and RecoveryCompletedNCT01587196Phase 2Results posted
• Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain PatientsCompletedNCT01559454Phase 4Results posted
• The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid DependenceCompletedNCT01556425Phase 2Results posted
• HIV, Buprenorphine, and the Criminal Justice SystemCompletedNCT01550341Not applicableResults posted
• 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical DependenceCompletedNCT01549652Not applicableResults posted
• Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion SurgeryCompletedNCT01531439Not applicableResults posted
• A Study of VIVITROL in the Prevention of Re-arrest and Re-incarcerationCompletedNCT01453374Phase 4Results posted
• Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer PainCompletedNCT01428583Phase 3Results posted
• Cocaine Use Reduction With BuprenorphineCompletedNCT01402492Phase 2/3Results posted
• A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)CompletedNCT01396005Phase 1Results posted
• A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced ConstipationCompletedNCT01395524Phase 3Results posted
• Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related PainTerminatedNCT01384292Phase 3Results posted
• Compassionate Use Study of MethylnaltrexoneCompletedNCT01368562Not applicableResults posted
• Treatment Strategy for Alcohol Use Disorders in Veterans With TBICompletedNCT01342549Phase 3Results posted
• Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced ConstipationCompletedNCT01336205Phase 3Results posted

← Opioid antagonists overview